Rina A. grew up on a corn farm in Nebraska and now lives in Debary, FL, with her soulmate and husband, John. She has worked at Stetson University for 20 years and is currently the presidential liaison for philanthropic [...]
On Dec. 18, 2024, the U.S. Food and Drug Administration (FDA) approved Ensacove (ensartinib) for people with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have an ALK mutation and have not previously received an ALK-targeted therapy. [...]
On September 19, 2024, the U.S. Food and Drug Administration (FDA) issued a new approval for the targeted therapy drug Rybrevant (amivantamab-vmjw) in combination with the existing combination chemotherapy treatment, Paraplatin (carboplatin) + Alimta (pemetrexed). The FDA approved this [...]
Contributing Authors: Brittney Nichols, MPH, RN-BSN, Senior Specialist, Science and Research, GO2 for Lung Cancer; Andrew Ciupek, PhD, Associate Director, Clinical Research, GO2 for Lung Cancer; and Renee Botello, MSc, Navigator, Treatment and Trials, GO2 for Lung Cancer Every [...]
Question: I was diagnosed with early-stage lung cancer. Do I need biomarker testing? Can I benefit from a targeted therapy if a biomarker is discovered? (Answered by Dr. Collin Blakely from the University of California, San Francisco, during his [...]
For people diagnosed with lung cancer, receiving a second opinion can be an important step in confirming treatment decisions or opting for a new approach to treatment. In Mary Burlie’s case, getting a second opinion changed everything. Although her [...]
Author: Brittney Nichols, MPH, BSN-RN, Senior Specialist, Science & Research, GO2 for Lung Cancer Biomarker testing is an important part of the cancer diagnosis and care continuum. For almost all people diagnosed with non-small cell lung cancer (NSCLC) biomarker [...]
Question: I was just diagnosed with lung cancer. My doctor told me that I should have biomarker testing done to determine the best treatment for me. What are biomarkers, and why will testing for them affect my treatment options? [...]
Author: GO2 for Lung Cancer Specialist, Science & Research, Brittney Nichols MPH, BSN-RN Each year, scientists and doctors from across the globe gather at IASLC’s World Conference on Lung Cancer (WCLC) to discuss the latest and greatest in lung [...]
Author: GO2 for Lung Cancer Associate Director, Clinical Research, Andrew Ciupek, PhD With an increasing number of targeted therapies becoming available, making treatment decisions based on the results of biomarker testing has become an essential part of cancer care [...]